Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 11 clinical trials
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP)

strategies in PSP. Trials of cholinesterase inhibitors in PSP have produced rather conflicting results: donepezil improves cognition but deteriorates some motor functions whereas a case series of 5

parkinson's disease
screening procedures
mini-mental state examination
gaze palsy
  • 23 Feb, 2022
  • 1 location
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (CHIEF PD)

> Cholinesterase inhibitor (ChEis) are drugs that are currently used to treat people with memory problems in Parkinson's. The effect of these drugs on falls in Parkinson's has been tested to show that treatment

  • 23 Feb, 2022
  • 27 locations
Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients?

This study will look at the incidence of post-spinal shivering (PSS) among the obstetrics population and will investigate whether higher operation theater (OT) temperature range or/and IV Ondansetron are able to reduce the incidence of PSS. This is a double-blind, randomized, factorial study, patients will be grouped into 4 groups …

Accepts healthy volunteers
  • 21 Oct, 2021
  • 1 location
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (LUCINDA)

The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of donepezil (Aricept.) Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) …

cognitive impairment
alzheimer's disease
mild cognitive impairment
  • 28 Feb, 2022
  • 1 location
tDCS on Parkinson's Disease Cognition (tDCS-PD-fMRI)

dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil

brain stimulation
cognitive impairment
cholinesterase inhibitors
motor symptoms
  • 20 Apr, 2022
  • 1 location
Cortical Excitability in AD-AHeAD

The aim of this study is to understand the relationship between brain excitability, neuroimaging, and cognitive function in early Alzheimer's disease in order to help develop future treatments. Participants are followed over 18 months.

  • 03 Mar, 2022
  • 1 location
Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD)

The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) [D+Q], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans …

alzheimer's disease
body mass index
progression of alzheimer's disease
  • 24 Jan, 2022
  • 1 location
The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.

Purpose: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the therapeutic effects of donepezil in radiotherapy-related cognitive impairment. Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University / Yameitang. Primary outcome measure: cognitive improvement, which is determined by the difference value of ADAS-cog score before …

mini-mental state examination
  • 19 Feb, 2022
  • 1 location
Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second line treatment for overactive bladder syndrome. However, theoretically, undesirable effect of the anti-muscarinic agent such as dry mouth and constipation would make it less suitable …

  • 20 Aug, 2021
  • 1 location
Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment …

brief psychotic disorder
schizoaffective disorder
  • 14 Mar, 2022
  • 1 location